Literature DB >> 25012652

Identification and functional characterization of nuclear mortalin in human carcinogenesis.

Jihoon Ryu1, Zeenia Kaul2, A-Rum Yoon3, Ye Liu4, Tomoko Yaguchi4, Youjin Na3, Hyo Min Ahn1, Ran Gao4, Il-Kyu Choi3, Chae-Ok Yun5, Sunil C Kaul6, Renu Wadhwa7.   

Abstract

The Hsp70 family protein mortalin is an essential chaperone that is frequently enriched in cancer cells and exists in various subcellular sites, including the mitochondrion, plasma membrane, endoplasmic reticulum, and cytosol. Although the molecular mechanisms underlying its multiple subcellular localizations are not yet clear, their functional significance has been revealed by several studies. In this study, we examined the nuclear fractions of human cells and found that the malignantly transformed cells have more mortalin than the normal cells. We then generated a mortalin mutant that lacked a mitochondrial targeting signal peptide. It was largely localized in the nucleus, and, hence, is called nuclear mortalin (mot-N). Functional characterization of mot-N revealed that it efficiently protects cancer cells against endogenous and exogenous oxidative stress. Furthermore, compared with the full-length mortalin overexpressing cancer cells, mot-N derivatives showed increased malignant properties, including higher proliferation rate, colony forming efficacy, motility, and tumor forming capacity both in in vitro and in vivo assays. We demonstrate that mot-N promotes carcinogenesis and cancer cell metastasis by inactivation of tumor suppressor protein p53 functions and by interaction and functional activation of telomerase and heterogeneous ribonucleoprotein K (hnRNP-K) proteins.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cancer Biology; Heat Shock Protein (HSP); Mortalin; Nuclear Localization; Telomerase; Telomerase Activation; Tumor Promoter; hnRNP-K; p53; p53 Inactivation

Mesh:

Substances:

Year:  2014        PMID: 25012652      PMCID: PMC4155653          DOI: 10.1074/jbc.M114.565929

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Mortalin controls centrosome duplication via modulating centrosomal localization of p53.

Authors:  Z Ma; H Izumi; M Kanai; Y Kabuyama; N G Ahn; K Fukasawa
Journal:  Oncogene       Date:  2006-04-17       Impact factor: 9.867

Review 2.  Three faces of mortalin: a housekeeper, guardian and killer.

Authors:  Sunil C Kaul; Custer C Deocaris; Renu Wadhwa
Journal:  Exp Gerontol       Date:  2006-12-22       Impact factor: 4.032

3.  TAK1 represses transcription of the human telomerase reverse transcriptase gene.

Authors:  T Fujiki; T Miura; M Maura; H Shiraishi; S Nishimura; Y Imada; N Uehara; K Tashiro; S Shirahata; Y Katakura
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

4.  Physical and functional interaction between mortalin and Mps1 kinase.

Authors:  Masayuki Kanai; Zhiyong Ma; Hideki Izumi; Song-Hee Kim; Christopher P Mattison; Mark Winey; Kenji Fukasawa
Journal:  Genes Cells       Date:  2007-06       Impact factor: 1.891

5.  The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells.

Authors:  Vassilis Papanikolaou; Dimitrios Iliopoulos; Ioannis Dimou; Stephanie Dubos; Ioannis Tsougos; Kyriaki Theodorou; Sofia Kitsiou-Tzeli; Aspasia Tsezou
Journal:  Int J Oncol       Date:  2009-11       Impact factor: 5.650

6.  PKCdelta regulates the stimulation of vascular endothelial factor mRNA translation by angiotensin II through hnRNP K.

Authors:  Kavithalakshmi Sataranatarajan; Myung-Ja Lee; Meenalakshmi M Mariappan; Denis Feliers
Journal:  Cell Signal       Date:  2008-02-01       Impact factor: 4.315

7.  Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.

Authors:  David Pilzer; Moran Saar; Keizo Koya; Zvi Fishelson
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

8.  Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence.

Authors:  Xin Yi; John M Luk; Nikki P Lee; Jirun Peng; Xisheng Leng; Xin-Yuan Guan; George K Lau; Laura Beretta; Sheung-Tat Fan
Journal:  Mol Cell Proteomics       Date:  2007-10-14       Impact factor: 5.911

9.  Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells.

Authors:  X Kang; W Chen; R H Kim; M K Kang; N-H Park
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

Review 10.  Targeting telomerase for cancer therapeutics.

Authors:  J W Shay; W N Keith
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more
  36 in total

1.  Circulating mortalin autoantibody--a new serological marker of liver cirrhosis.

Authors:  Wen-Jing Lu; Nishant Saxena; John M Luk; Sunil C Kaul; Renu Wadhwa
Journal:  Cell Stress Chaperones       Date:  2015-04-24       Impact factor: 3.667

2.  Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease.

Authors:  Renu Wadhwa; Jihoon Ryu; Hyo Min Ahn; Nishant Saxena; Anupama Chaudhary; Chae-Ok Yun; Sunil C Kaul
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

Review 3.  Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR.

Authors:  Pan Deng; Cole M Haynes
Journal:  Semin Cancer Biol       Date:  2017-05-10       Impact factor: 15.707

Review 4.  The Role of Heat Shock Protein 70 Subfamily in the Hyperplastic Prostate: From Molecular Mechanisms to Therapeutic Opportunities.

Authors:  Xun Fu; Huan Liu; Jiang Liu; Michael E DiSanto; Xinhua Zhang
Journal:  Cells       Date:  2022-06-28       Impact factor: 7.666

Review 5.  Why is Mortalin a Potential Therapeutic Target for Cancer?

Authors:  A-Rum Yoon; Renu Wadhwa; Sunil C Kaul; Chae-Ok Yun
Journal:  Front Cell Dev Biol       Date:  2022-06-29

6.  ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells.

Authors:  Bo-Kyeong Jung; Young Jun Kim; JinWoo Hong; Han-Gyu Chang; A-Rum Yoon; Chae-Ok Yun
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

7.  Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability.

Authors:  Pui-Kei Wu; Seung-Keun Hong; Wenjing Chen; Andrew E Becker; Rebekah L Gundry; Chien-Wei Lin; Hao Shao; Jason E Gestwicki; Jong-In Park
Journal:  Sci Signal       Date:  2020-03-10       Impact factor: 8.192

8.  Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.

Authors:  Sanam Sane; Ammara Abdullah; Morgan E Nelson; Hongmin Wang; Subhash C Chauhan; Samuel S Newton; Khosrow Rezvani
Journal:  Cell Stress Chaperones       Date:  2015-12-04       Impact factor: 3.667

9.  27-Hydroxycholesterol is a specific factor in the neoplastic microenvironment of HCC that causes MDR via GRP75 regulation of the redox balance and metabolic reprogramming.

Authors:  Ming Jin; Ye Yang; Yi Dai; Rong Cai; Liunan Wu; Yuwen Jiao; Zhan Zhang; Haojun Yang; Yan Zhou; Liming Tang; Lei Li; Yuan Li
Journal:  Cell Biol Toxicol       Date:  2021-04-20       Impact factor: 6.691

10.  Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.

Authors:  Nupur Nigam; Abhinav Grover; Sukriti Goyal; Shashank P Katiyar; Priyanshu Bhargava; Pi-Chao Wang; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.